Nanobiotix (NBTX) Liabilities and Shareholders Equity (2018 - 2025)

Nanobiotix's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $78.9 million for Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity rose 9.48% year-over-year to $78.9 million in Q4 2025; TTM through Dec 2025 was $295.4 million, a 4.84% decrease from a year earlier, with the FY2025 full-year figure at $76.6 million, up 6.26% from the prior year.
• Liabilities and Shareholders Equity grew to $78.9 million in Q4 2025 per NBTX's latest filing, from $51.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $149.2 million in Q2 2021 and bottomed at $44.0 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $82.5 million (2022), against an average of $85.3 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 48.86% in 2023 and soared 112.15% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $116.4 million in 2021, then slumped by 47.62% to $61.0 million in 2022, then surged by 65.68% to $101.0 million in 2023, then dropped by 28.69% to $72.0 million in 2024, then rose by 9.48% to $78.9 million in 2025.
• Per Business Quant, the three latest NBTX Liabilities and Shareholders Equity figures stand at $78.9 million (Q4 2025), $51.1 million (Q2 2025), and $72.0 million (Q4 2024).